新指南新工具 CRUSADE评分及出血规避策略培训课件.pptVIP

. . . . . 中文版 . . . . . . . . . . * This slide places our findings in the context of prior studies of antiplatelet therapy in ACS. The introduction of single antiplatelet therapy with aspirin, as summarized in the APTC report, was associated with a 22% reduction in ischemic events. Moving to dual antiplatelet therapy with 氯吡格雷 + aspirin in CURE produced a further 20% reduction in ischemic events. The higher IPA achieved with the combination of 普拉格雷 and aspirin produced yet a further 19% reduction in ischemic events. Each of these advances in antiplatelet therapy was associated with a progres